Coronavirus (COVID-19) Statement

We continue to closely monitor the situation surrounding the COVID-19 pandemic and are following the published recommendations of the CDC, American Academy of Ophthalmology and American Optometric Association by canceling all routine patient appointments. We will continue to see only patients with urgent/emergent needs at all of our locations.

For our offices that remain open, we remain focused on the health and safety of our patients and staff, and avoiding further spread of the virus through the implementation of the following protocols:

1) We have greatly expanded measures to disinfect our office including cleaning between each patient appointment.

2) To limit any potential exposure, we ask you NOT to bring any non-essential person(s) with you to the appointment.

3) If someone must accompany you to your appointment, we ask that they do not enter the office, if at all possible.

4) If you have an upcoming appointment and identify with the following statements, please do not come directly to the office, but instead call us:

• Fever greater than 100.4

• Respiratory symptoms or difficulty breathing

• Exposed to someone with COVID-19 in the past 14 days

• Placed in self/hospital quarantine by medical doctor

 Your health and that of our staff is our guiding priority and we continue to update our protocol to ensure safety for everyone. If you have questions regarding these evolving protocols, please contact our office.

A VISION TO BE THE BEST      

A- A A+

A Vision to be the Best

As the largest group of Retina specialists in the Greater Kansas City, Topeka, Sedalia and surrounding areas we offer multiple professional offices to serve you.  Each of our offices are staffed and equipped to provide the highest level of health care service and access in a comfortable environment.

Ryan D. Christensen, M.D.

Dr. Christensen CURRICULUM VITAE

NAME

  • Ryan D. Christensen, M.D.

BIRTHDATE

  • April 16, 1977; Garden City, Kansas

WORK HISTORY

2010 - PRESENT:

  • Retina Associates, P.A.
    Santa Fe Medical Building
    9301 West 74th Street
    Suite 210
    Shawnee Mission, KS 66204
  • Retina Associates, P.A.
    6201 College Boulevard
    Suite 200
    Overland Park, KS 66211
  • Retina Associates. P.A.
    10100 N Ambassador Drive
    Suite 100
    Kansas City, MO 64153
  • Retina Associates, P.A.
    6001 SW 6th Avenue
    Suite 300
    Topeka, KS 66615
  • Retina Associates, P.A.
    3700 W 10th Street
    Suite 101
    Sedalia, MO 65301
  • Retina Associates, P.A.
    100 NE Missouri Road
    Suite 203
    Lee's Summit, MO 64086

EDUCATION:

  • Retina Associates, P.A. – Shawnee Mission, KS 2008-2010
    -Vitreoretinal Fellowship
  • University of Kansas School of Medicine – Kansas City, KS 2005-2008
    -Ophthalmology residency
  • University of Kansas School of Medicine – Wichita, KS 2003-2004
    -Internal Medicine internship
  • University of Kansas School of Medicine – Wichita, KS 2002-2004
    -Clinical clerkship – medical school
  • University of Kansas School of Medicine – Kansas City, KS 2000-2002
    -Basic science clerkship – medical school
  • Kansas State University – Manhattan, KS 1995-2000
    -Bachelor of Science – Biology
  • Garden City Community College – Garden City, KS 1996-1997
  • Garden City High School – Garden City, KS 1991-1995

RESEARCH:

  • Eyetech: EOP1024, Sub-Investigator,
    Evaluating the effects of Intravitreal
    Injections of Pegaptanib for NVAMD
    on the corneal endothelium 2010-present
  • Genentech: FVF4168g, Sub-Investigator,
    Intravitreal Injection of Ranibizumab for
    Diabetic Macular Edema 2008-present
  • Genentech: FVF4166g, Sub-Investigator,
    Intravitreal Injection of Ranibizumab for
    Central Retinal Vein Occlusion 2008-2010
  • Genentech: FVF4165g, Sub-Investigator,
    Intravitreal Injection of Ranibizumab for
    Branch Retinal Vein Occlusion 2008-2010
  • Genentech: FVF3426g, Sub-Investigator,
    Intravitreal Injection of Ranibizumab for
    BRVO & CRVO patients who completed
    Genentech sponsored Ranibizumab Study 2009-2010
  • Genentech: FVF4579g, Sub-Investigator,
    Intravitreal Injection of Ranibizumab for
    Subfoveal Neovascular AMD 2009-present
  • Genentech: FVF4967g, Sub-Investigator,
    Intravitreal Injection of Ranibizumab for
    BRVO, CRVO, & HRVO study to start 2/2011
  • Ophthotech: OPH3000, Sub-Investigator,
    Intravitreal Injection of Volocixumab in
    combination with Ranibizumab for NVAMD 2008-2009
  • Ophthotech: OPH1001, Sub-Investigator,
    Intravitreal Injection of E10030 in
    combination with Ranibizumab for NVAMD 2010-present

SCHOLARLY PRESENTATIONS

  • “Fluorescein Angiography #101” 2008/09
    -KU Eye
    -Monthly lecture series
  • “Posterior Parasitic Uveitis” 11/2007
    -KU Eye Grand Rounds
  • “Parasitic Uveitis: Worm in the Eye!!" 02/2007
    -High Plain’s Eye Society Winter Symposium
  • “Adherence to Preferred Practice Patterns in ARMD” 06/2007
    -KU Eye Grand Rounds
  • “AAO Mid-Year Forum 2007” 06/2007
    -KU Eye Grand Rounds
  • “Orbital Masses – A Differential Diagnosis” 05/2007
    -Children’s Mercy Hospital Grand Rounds
  • "Eyelid Tumors - Clinical Diagnosis and Histology 101" 09/2006
    -KU Eye Grand Rounds
  • "Herpetic Corneal Disorders" 07/2006
    -KU Eye New Resident Orientation
  • "Common Corneal Disorders" 07/2006
    -KU Eye New Resident Orientation
  • "Cogan's Syndrome - Oculovestibuloauditory Syndrome" 06/2006
    -KU Eye Resident Research Day
  • "LASIK and Excimer Laser Evolution" 03/2006
    -KU Eye Grand Rounds
  • "Aceruloplasminemia – Fundus and Fluorescein Angiography" 04/2006
    - KU Medical Center Internal Medicine Grand Rounds
  • "The Red Eye - A Differential Diagnosis" 07/2005
    -KU Medical Center Pediatrics Morning Report

A Vision to be the Best

Retina Associates, PA

9301 W 74th St Ste 210
Shawnee Mission, KS 66204

 

Map of our location

Email Us

From (E-mail Address):
Hello, my name is I am interested in scheduling an appointment with your Retina Associates, P.A. and would like to receive information about
Please call me at at your earliest convenience. Thank You!